Skip to content
DraconiticResearch
Search Sources API
210,089 studies31 sourcesUpdated 35 min ago
Peer-reviewedCC BY-NC-ND 4.0Diabetes, Obesity & Metabolism

Intravenous Oxytocin Does Not Affect Glucose‐Regulating Hormones or Markers of Bone Turnover During Graded Glucose Infusion in Healthy Men

  • Vivian Kliim‐Hansen1
  • Ida M. Gether1
  • Aliya M. Thomas1
  • Anne‐Marie Ellegaard1,2
  • Miriam G. Pedersen1
  • Jens J. Holst2,3
  • Bolette Hartmann2
  • Filip K. Knop1,4,5
  • Lærke S. Gasbjerg1,2
  • Asger B. Lund1,4,6
6 affiliations
  1. 1Center for Clinical Metabolic Research, Copenhagen University Hospital—Herlev and Gentofte Hellerup Denmark
  2. 2Department of Biomedical Sciences, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark
  3. 3Novo Nordisk Foundation Center for Basic Metabolic Research, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark
  4. 4Department of Clinical Medicine, Faculty of Health and Medical Sciences University of Copenhagen Copenhagen Denmark
  5. 5Novo Nordisk A/S Søborg Denmark
  6. 6Clinical Research, Steno Diabetes Center Copenhagen Herlev Denmark
Read full textPDFDOICite

Abstract

Aim: Oxytocin has been proposed to exert glucose‐stabilising effects via modulation of pancreatic hormone secretion and to play a role in bone homeostasis. However, human data under controlled conditions are limited. We investigated the effects of intravenously infused oxytocin during a graded glucose infusion on glucose‐regulating hormones and markers of bone turnover in healthy men.

Materials and Methods: In a randomised, placebo‐controlled, double‐blind, crossover study, healthy men received intravenous infusions of oxytocin (0.1 or 0.2 IU/min, or placebo [saline], respectively) on three separate days during a three‐hour intravenous graded glucose infusion with increases every 30 min (2–12 mg/kg/min). The primary outcome was baseline‐subtracted area under the curve for C‐peptide concentrations. Secondary outcomes included concentrations of plasma glucose, glucagon, glucose‐dependent insulinotropic polypeptide (GIP), glucagon‐like peptide 1 (GLP‐1), carboxy‐terminal collagen crosslink (CTX), procollagen Type 1 amino‐terminal propeptide (P1NP) and serum triglycerides.

Results: Twenty men (age: 24.9 ± 3.2 years; BMI: 23.8 ± 1.5 kg/m2) were included. Peak plasma oxytocin concentrations: 193 ± 29 and 401 ± 66 pg/mL. Circulating concentrations of plasma glucose, C‐peptide, glucagon, GIP, GLP‐1, CTX, P1NP and triglyceride were similar across study visits. Neither oxytocin dose affected C‐peptide response or any secondary metabolic outcomes compared with placebo.

Conclusion: Acute intravenous oxytocin infusion resulting in supraphysiological plasma concentrations did not modulate pancreatic or gut hormone secretion, or markers of bone turnover during a controlled, stepwise glucose challenge in healthy men, suggesting limited acute metabolic and skeletal effects of oxytocin under these conditions.

Related

  1. The Effect of Pharmacological and Non-Pharmacological Interventions on Headaches Induced by Intravenous Nitroglycerin Infusion: A Systematic Review.
    Fatemeh Ahmadi, Masoumeh Bagheri Nesami, Mobina Abedinpour
    Journal of cardiovascular and thoracic researchPeer-reviewedCC BYFull textPsychiatry & mental healthEurope PMC
  2. The clinical effects of an intravenous perioperative lidocaine infusion during hepatectomy: a pilot study.
    Sergiu Sargarovschi, Andreea Abouritei, Ioana Rucsanda +3
    Medicine and pharmacy reportsPeer-reviewedCC BY-NC-NDFull textSurgery & anaesthesiaEurope PMCPMC
  3. Development and external validation of a risk prediction model for early peripheral intravenous catheter failure in outpatients and emergency department patients receiving consecutive infusion therapy.
    Jingjue Mao, Caifeng Xu, Yuxin Yao +7
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Glargine-to-intravenous insulin dose ratio, rebound hyperglycemia and hypoglycemia after discontinuation of insulin infusion in critically ill adults: a retrospective cohort study
    L. Shao, Y. Li, L. Wang +1
    medRxivPreprintPublic domainFull textEndocrinology & metabolismmedRxiv
  5. Clinical Outcomes and Inflammatory Biomarker Changes After Intravenous Ketamine-Lidocaine Infusion in Refractory Neuropathic Pain: A Prospective Observational Pilot Study.
    Ivan Keser, Slavenka Straus, Denis Imamovic +5
    CureusPeer-reviewedCC BYFull textPhysiologyEurope PMC

Cite

BibTeXRIS
BibTeX
@article{kliimhansen2026intravenous,
  title = {{Intravenous Oxytocin Does Not Affect Glucose‐Regulating Hormones or Markers of Bone Turnover During Graded Glucose Infusion in Healthy Men}},
  author = {Vivian Kliim‐Hansen and Ida M. Gether and Aliya M. Thomas and Anne‐Marie Ellegaard and Miriam G. Pedersen and Jens J. Holst and Bolette Hartmann and Filip K. Knop and Lærke S. Gasbjerg and Asger B. Lund},
  journal = {Diabetes, Obesity \& Metabolism},
  year = {2026},
  month = sep,
  doi = {10.1111/dom.71292},
  url = {https://doi.org/10.1111/dom.71292},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Intravenous Oxytocin Does Not Affect Glucose‐Regulating Hormones or Markers of Bone Turnover During Graded Glucose Infusion in Healthy Men
AU  - Vivian Kliim‐Hansen
AU  - Ida M. Gether
AU  - Aliya M. Thomas
AU  - Anne‐Marie Ellegaard
AU  - Miriam G. Pedersen
AU  - Jens J. Holst
AU  - Bolette Hartmann
AU  - Filip K. Knop
AU  - Lærke S. Gasbjerg
AU  - Asger B. Lund
PY  - 2026
DA  - 2026/09/03
JO  - Diabetes, Obesity & Metabolism
DO  - 10.1111/dom.71292
UR  - https://doi.org/10.1111/dom.71292
AB  - Aim: Oxytocin has been proposed to exert glucose‐stabilising effects via modulation of pancreatic hormone secretion and to play a role in bone homeostasis. However, human data under controlled conditions are limited. We investigated the effects of intravenously infused oxytocin during a graded glucose infusion on glucose‐regulating hormones and markers of bone turnover in healthy men.  Materials and Methods: In a randomised, placebo‐controlled, double‐blind, crossover study, healthy men received intravenous infusions of oxytocin (0.1 or 0.2 IU/min, or placebo [saline], respectively) on three separate days during a three‐hour intravenous graded glucose infusion with increases every 30 min (2–12 mg/kg/min). The primary outcome was baseline‐subtracted area under the curve for C‐peptide concentrations. Secondary outcomes included concentrations of plasma glucose, glucagon, glucose‐dependent insulinotropic polypeptide (GIP), glucagon‐like peptide 1 (GLP‐1), carboxy‐terminal collagen crosslink (CTX), procollagen Type 1 amino‐terminal propeptide (P1NP) and serum triglycerides.  Results: Twenty men (age: 24.9 ± 3.2 years; BMI: 23.8 ± 1.5 kg/m2) were included. Peak plasma oxytocin concentrations: 193 ± 29 and 401 ± 66 pg/mL. Circulating concentrations of plasma glucose, C‐peptide, glucagon, GIP, GLP‐1, CTX, P1NP and triglyceride were similar across study visits. Neither oxytocin dose affected C‐peptide response or any secondary metabolic outcomes compared with placebo.  Conclusion: Acute intravenous oxytocin infusion resulting in supraphysiological plasma concentrations did not modulate pancreatic or gut hormone secretion, or markers of bone turnover during a controlled, stepwise glucose challenge in healthy men, suggesting limited acute metabolic and skeletal effects of oxytocin under these conditions.
SN  - 1462-8902
SN  - 1463-1326
ER  -